Payment overview · 2025
General Payments
$852.12
57 reported records · 21 companies
Healthcare provider profile · identity verified
Sara Patry, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HUTCHINSON, KS · NPI 1679955363
Verified facts
What the public records show
CMS Open Payments records show Sara Patry, M.D. received $852.12 in general payments during 2025 across 57 reported records.
Novo Nordisk Inc accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $225.39 | 26.4% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $138.17 | 16.2% | 13 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $73.78 | 8.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $53.40 | 6.3% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.23 | 4.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.50 | 3.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.54 | 3.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.15 | 3.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $28.99 | 3.4% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $26.03 | 3.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.15 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.08 | 2.0% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $16.60 | 1.9% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $16.24 | 1.9% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $16.13 | 1.9% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.03 | 1.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.98 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.15 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.32 | 1.7% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $14.14 | 1.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $14.12 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $852.12 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $219.33 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $186.17 | 12 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $95.91 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $53.40 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.26 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.26 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.40 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.23 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.54 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.15 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $28.99 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $26.03 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $26.03 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1023 | 249 |
| Levothyroxine Sodium | Levothyroxine Sodium | 998 | 217 |
| Losartan Potassium | Losartan Potassium | 834 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 640 | 151 |
| Omeprazole | Omeprazole | 630 | 146 |
| Pantoprazole Sodium | Pantoprazole Sodium | 582 | 127 |
| Lisinopril | Lisinopril | 551 | 127 |
| Furosemide | Furosemide | 543 | 107 |
| Gabapentin | Gabapentin | 531 | 98 |
| Simvastatin | Simvastatin | 526 | 124 |
| Potassium Chloride | Potassium Chloride | 432 | 90 |
| Metformin Hcl | Metformin Hcl | 368 | 86 |
| Sertraline Hcl | Sertraline Hcl | 351 | 80 |
| Trazodone Hcl | Trazodone Hcl | 295 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 294 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 62 |
| Tramadol Hcl | Tramadol Hcl | 270 | 60 |
| Montelukast Sodium | Montelukast Sodium | 262 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 244 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 232 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 209 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 207 | 31 |
| Carvedilol | Carvedilol | 204 | 43 |
| Alprazolam | Alprazolam | 202 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 200 | 55 |
| Prednisone | Prednisone | 173 | 101 |
| Finasteride | Finasteride | 168 | 40 |
| Meloxicam | Meloxicam | 162 | 41 |
| Donepezil Hcl | Donepezil Hcl | 161 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 153 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 29 |
| Atenolol | Atenolol | 147 | 33 |
| Warfarin Sodium | Warfarin Sodium | 143 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 38 |
| Clonazepam | Clonazepam | 141 | 18 |
| Pregabalin | Pregabalin | 140 | 21 |
| Eliquis | Apixaban | 136 | 20 |
| Allopurinol | Allopurinol | 132 | 31 |
| Buspirone Hcl | Buspirone Hcl | 130 | 26 |
| Glipizide Er | Glipizide | 128 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 124 | 17 |
| Xarelto | Rivaroxaban | 124 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 39 |
| Bupropion Xl | Bupropion Hcl | 117 | 18 |
| Baclofen | Baclofen | 115 | 25 |
| Famotidine | Famotidine | 115 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 112 | 30 |
| Mirtazapine | Mirtazapine | 112 | 19 |
| Azithromycin | Azithromycin | 108 | 51 |
| Ropinirole Hcl | Ropinirole Hcl | 107 | 18 |
| Metformin Hcl Er | Metformin Hcl | 104 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 100 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 93 | 11 |
| Lovastatin | Lovastatin | 91 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | 22 |
| Levetiracetam | Levetiracetam | 88 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 87 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 24 |
| Ozempic | Semaglutide | 77 | 18 |
| Topiramate | Topiramate | 72 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 71 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 71 | 13 |
| Lorazepam | Lorazepam | 67 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 22 |
| Propranolol Hcl | Propranolol Hcl | 65 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 13 |
| Spironolactone | Spironolactone | 64 | 16 |
| Alendronate Sodium | Alendronate Sodium | 63 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 46 |
| Ezetimibe | Ezetimibe | 60 | 15 |
| Synthroid | Levothyroxine Sodium | 60 | 18 |
| Estradiol | Estradiol | 59 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | 12 |
| Primidone | Primidone | 57 | 11 |
| Jardiance | Empagliflozin | 56 | suppressed |
| Fluconazole | Fluconazole | 55 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 55 | suppressed |
| Celecoxib | Celecoxib | 54 | 14 |
| Myrbetriq | Mirabegron | 54 | suppressed |
| Glimepiride | Glimepiride | 52 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 50 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 12 |
| Ondansetron Odt | Ondansetron | 49 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 40 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | suppressed |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Cephalexin | Cephalexin | 46 | 33 |
| Clonidine Hcl | Clonidine Hcl | 46 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 46 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 46 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 30 |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 40 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 39 | suppressed |
| Bumetanide | Bumetanide | 39 | 11 |
| Carbamazepine | Carbamazepine | 39 | suppressed |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 27 |
| Nystatin | Nystatin | 38 | 20 |
| Naproxen | Naproxen | 37 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 37 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 14 |
| Acyclovir | Acyclovir | 32 | suppressed |
| Gemtesa | Vibegron | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Loperamide | Loperamide Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 18 |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 20 |
| Temazepam | Temazepam | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 22 | suppressed |
| Niacin Er | Niacin | 22 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 17 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Felodipine Er | Felodipine | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $852.12 · 57 records | Novo Nordisk Inc | AREXVY, Cologuard Collection Kit, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, GEMTESA, INSPIRE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, Quviviq, REPATHA, REXULTI, Rybelsus, Rystiggo, SHINGRIX, Tymlos, UPTRAVI, VOQUEZNA, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error